---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-24-000030"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:45:06.620597+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Travere Q2 FILSPARI sales $27.1M, up 37% Q/Q; 521 new patient start forms

## Summary
- Net product sales $52.2M (incl. $27.1M FILSPARI); total revenue $54.1M.
- Net loss $70.4M ($0.91/share); adjusted net loss $50.1M ($0.65/share).
- Cash & equivalents $325.4M at June 30, 2024.
- PDUFA target date Sept 5, 2024 for FILSPARI full approval in IgAN.
- Received 521 PSFs in Q2; 2,484 total since launch.

## SEC filing metadata
- accession: 0001438533-24-000030
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000030/0001438533-24-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000030/tvtx-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-24-000030
- JSON: https://secwatch.observer/filing/0001438533-24-000030.json
- Plain text: https://secwatch.observer/filing/0001438533-24-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.